Striverdi Respimat

Showing 1 posts of 1 posts found.

Boehringer assures future growth following sales drop

April 23, 2015
Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results

Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …

The Gateway to Local Adoption Series

Latest content